Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes

Diabetes

Volumn 57, Issue 4, 2008, Pages 929-937

  Pfleger, Christian ^a   Mortensen, Henrik B ^b   Hansen, Lars ^c   Herder, Christian ^a   Roep, Bart O ^d   Hoey, Hillary ^e   Aanstoot, Henk Jan ^f   Kocova, Mirjana ^g   Schloot, Nanette C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ADELAIDE AND MEATH HOSPITAL   (Ireland)

^f Diabetes Center for Pediatric and Adolescent Diabetes   (Netherlands)

^g Paediatric Clinic   (Macedonia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; IL1RAP PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CELL FUNCTION; CHILD; FEMALE; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SERUM; SEX; BLOOD; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; LONGITUDINAL STUDY; METABOLISM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADIPONECTIN; ADOLESCENT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFANT; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LONGITUDINAL STUDIES; MALE;

EID: 42449141905     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1697     Document Type: Article

References (49)

1. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229, 2001
2. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic β-Cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl. 2):S97-S107, 2005
3. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I: Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774-779, 2006
4. Larsen CM, Dossing MG, Papa S, Franzoso G, Billestrup N, Mandrup-Poulsen T: Growth arrest-and DNA-damage-inducible 45beta gene inhibits c-Jun N-terminal kinase and extracellular signal-regulated kinase and decreases IL-1beta-induced apoptosis in insulin-producing INS-1E cells. Diabetologia 49:980-989, 2006
5. Petersen LG, Storling J, Heding P, Li S, Berezin V, Saldeen J, Billestrup N, Bock E, Mandrup-Poulsen T: IL-1beta-induced pro-apoptotic signalling is facilitated by NCAM/FGF receptor signalling and inhibited by the C3d ligand in the INS-1E rat beta cell line. Diabetologia 49:1864-1875, 2006
6. Steer SA, Scarim AL, Chambers KT, Corbett JA: Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoSMed 3:e17, 2006
7. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, Alizadeh BZ, Saha MT, Knip M, Devendra D, Wilkin T, Bonifacio E, Roep BO, Kolb H, Mandrup-Poulsen T: Association of immune mediators at diagnosis of type 1 diabetes with later clinical remission. Diabet Med 24:512-520, 2007
8. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL: Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 44:325-332, 2001
9. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H: An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52:1137-1142, 2003
10. Hanifi-Moghaddam P, Kappler S, Seissler J, Muller-Scholze S, Martin S, Roep BO, Strassburger K, Kolb H, Schloot NC: Altered chemokine levels in individuals at risk of type 1 diabetes mellitus. Diabet Med 23:156-163, 2006
11. Kagi D, Ho A, Odermatt B, Zakarian A, Ohashi PS, Mak TW: TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 162:4598-4605, 1999
12. Kristiansen OP, Mandrup-Poulsen T: Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 (Suppl. 2):S114-S124, 2005
13. Celi F, Bini V, Papi F, Santilli E, Castellani MS, Ferretti A, Mencacci M, Berioli MG, De Giorgi G, Falorni A: Circulating adipocytokines in non-diabetic and type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabet Med 23:660-665, 2006
14. Martos-Moreno GA, Barrios V, Soriano-Guillen L, Argente J: Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur J Endocrinol 155:757-761, 2006
15. Kolb H, Mandrup-Poulsen T: An immune origin of type 2 diabetes? Diabetologia 48:1038-1050, 2005
16. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526, 2007
17. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095-2147, 1996
18. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E: SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991, 2000
19. Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T: Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193:263-269, 2001
20. Shi H, Tzameli I, Bjorbaek C, Flier JS: Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279:34733-34740, 2004
21. Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H: Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 (Suppl. 2):S11-S17, 2005
22. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45:805-812, 2002
23. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA100:7265-7270, 2003
24. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA: Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54:2305-2313, 2005
25. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
26. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
27. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
28. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA: Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688-2697, 2006
29. de Beaufort CE, Swift PG, Skinner CT, Aanstoot HJ, Aman J, Cameron F, Martul P, Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, Mortensen HB, Njolstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M: Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 30:2245-2250, 2007
30. Mortensen HB, Hougaard P: Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries: the Hvidore Study Group on Childhood Diabetes. Diabetes Care 20:714-720, 1997
31. Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, Atchison JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Martul P, Matsuura N, Schoenle EJ, Sovik O, Swift PG, Tsou RM, Vanelli M, Aman J: Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries: Hvidore Study Group on Childhood Diabetes. Diabet Med 15:752-759, 1998
32. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
33. Hekkala A, Knip M, Veijola R: Ketoacidosis at diagnosis of type 1 diabetes in children in northern Finland: temporal changes over 20 years. Diabetes Care 30:861-866, 2007
34. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-Cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264, 2004
35. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, Daneman D, Dorchy H, Garandeau P, Greene SA, Hoey H, Holl RW, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Sovik O, Swift PG, Tsou RM, Vanelli M, Aman J: Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care 24:1342-1347, 2001
36. Holl RW, Swift PG, Mortensen HB, Lynggaard H, Hougaard P, Aanstoot HJ, Chiarelli F, Daneman D, Danne T, Dorchy H, Garandeau P, Greene S, Hoey HM, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Sovik O, Tsou RM, Vanelli M, Aman J: Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. EurJ Pediatr 162:22-29, 2003
37. Nielsen LB, Mortensen HB, Chiarelli F, Holl R, Swift P, de Beaufort C, Pociot F, Hougaard P, Gammeltoft S, Knip M, Hansen L: Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function. Diabetologia 49:71-74, 2006
38. Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92:1023-1033, 2007
39. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F, Burger D, Dayer JM, Meier CA: Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52:1104-1110, 2003
40. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM: IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184-1188, 2002
41. Rathmann W, Herder C: Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology." Horm Metab Res 39:1-2, 2007
42. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N: A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 54:194-199, 2005
43. Herder C, Hauner H, Haastert B, Rohrig K, Koenig W, Kolb H, Muller-Scholze S, Thorand B, Holle R, Rathmann W: Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care 29:1626-1631, 2006
44. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249-259, 2006
45. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
46. Yki-Jarvinen H, Koivisto VA: Natural course of insulin resistance in type I diabetes. N Engl J Med 315:224-230, 1986
47. Carey AL, Petersen EW, Bruce CR, Southgate RJ, Pilegaard H, Hawley JA, Pedersen BK, Febbraio MA: Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 49:1000-1007, 2006
48. Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reiffers-cheid A, Scherbaum WA, Kolb H, Martin S: The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression. J Mol Med 85:389-396, 2007
49. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, Akerblom HK, Knip M: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes: the Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 84:1534-1539, 1999